October , 2025
Dr._____________________________
________________ School of Medicine
Re: Letter of Support: NIH Proposal “____title________________________”
Dear Dr.___________ and colleagues:
I write in support of your ___________Research Consortium grant application entitled “_____________________” that you plan to submit to _________________________.
Greenstone Biosciences is a biotechnology company in Palo Alto, CA. At Greenstone Biosciences we utilize Artificial Intelligence to determine new drug targets and to make preclinical predictions regarding toxicity and pharmacokinetic and pharmacodynamic properties. In our paradigm, drug candidates are subsequently tested for biological validation using patient specific human induced pluripotent stem cells (hiPSC) in high throughput screens (HTS). We have a proprietary hiPSC Biobank containing >2000 patient cell lines to choose from for New Alternative Methods (NAMs) for drug testing to supplant the need to utilize animals for research. We are happy to work with your laboratory to draw hiPSCs from our Biobank for your project and/or to work with you to derive additional ____________________ Syndrome patient cell lines.
Further, our Biobank staff are trained in specialized hiPSC differentiation to a myriad of cell types and 3D organoids including: cardiovascular, pulmonary, hepatic, neuronal, intestinal, pancreatic and kidney. As an academic institution we can provide your laboratory with either hiPSCs or differentiated cells. Our specific products and services can be found at https://greenstonebio.com.
Our approach to drug discovery and development are in accord with recent federal agency mandates to utilize NAMs in place of animals for biomedical research. Working with Greenstone Biosciences will promote your laboratory’s adherence to these new federal agency policies and hasten the development of new therapies for patients.
We are happy to provide your group with assistance in high throughput drug toxicity prediction using AI and drug testing using the wide array of hiPSC derived NAMs that will be generated in a patient specific manner in this project. High Throughput Screening (HTS) is a strength of Greenstone’s laboratory, and we will assist you with HTS design, execution and interpretation.
Best regards,
Todd J. Herron, PhD
Greenstone Biosciences
Director, hiPSC Biobank